J Allergy Clin Immunol Glob . Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

[tetano]

J Allergy Clin Immunol Glob


. 2022 Aug;1(3):175-177.
doi: 10.1016/j.jacig.2022.04.005. Epub 2022 Apr 30.
Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose


Prudhvi Regula ¹ , David Rosenstreich ¹ , Elina Jerschow ¹ , Manish Ramesh ¹ , Denisa Ferastraoaru ¹ , Jessica Oh ¹ , Daniella S Aivazi ² , Jonathan M Aivazi ³ , Golda Hudes ¹



Affiliations

• PMID: 36164368
• PMCID: PMC9055417
• DOI: 10.1016/j.jacig.2022.04.005

Abstract

Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

Keywords: COVID-19 vaccines; COVID-19, Coronavirus disease 2019; Graded dosing of vaccine; PEG, Polyethylene glycol; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; mRNA vaccine allergy; vaccine desensitization; vaccine hesitancy.